I'm cautious about Novo Nordisk's short-term prospects due to the recent selloff, but see long-term potential with high ...

Digital health companies' plans focused on managing the impact of GLP-1 drugs, which have placed enormous pressure on health ...

Novo Nordisk has announced plans to move its ziltivekimab into phase 3 clinical development in atherosclerosis with chronic kidney disease after a mid-stage trial met its main goal.

Purpose: The educational content of direct-to-consumer (DTC) fulfillment materials was evaluated ... depression, diabetes, hypercholesterolemia, migraine, overactive bladder, and osteoporosis.

Getting to know what’s going on in your body can help you manage type 2 diabetes well. It’s a chronic condition in which your body doesn’t use insulin properly. This causes sugar to build up ...